Freedom of Information Request: 0956 2020/21
I am writing to request some data under the Freedom of Information Act. I am looking for numbers of Haemophilia A, Haemophilia B, and von Willebrand Disease patients on different treatment regimens and treatment types. I do not need any identifiers or information about specific brands or preferences.
Response includes Queen Elizabeth Hospital Birmingham patients receiving treatment in the 12 months from 1st September 2019 – 31st August 2020:
Haemophilia A
128 patients received treatment:
- 75 patients on prophylactic regimen, 53 patients on demand
- 111 patients received Recombinant Factor VIII
- 11 patients received Extended Half Life Recombinant FVIII
- 26 patients received monoclonal antibody treatment
- 7 patients received anti inhibitor coagulation complex
- 4 patients received Recombinant Factor VIIa
Haemophilia B
20 patients received treatment:
- 12 patients on prophylactic regimen, 8 patients on demand
- 19 patients received Recombinant Factor IX
- 1 patient received anti inhibitor coagulation complex and Recombinant Factor VIIa
Von Willebrand Disease
32 patients received treatment:
- 32 patients received Human Coagulation Factor and Human von Willebrand Factor
- 1 patient also received Human von Willebrand Factor alone
